ANURASAnupam Rasayan India Ltd.
Anupam Rasayan India Q2 FY27 Results: Consolidated Net Profit ₹64.97 Crore on Total Income of ₹821 Crore
- Earnings
- specialty chemicals
Reviewed byKeshav SehgalBlacklitt Research
Anupam Rasayan India (NSE: ANURAS) reported consolidated total income of ₹821.17 crore and net profit of ₹64.97 crore for the quarter ended 30 Sep 2026, it said in a filing on 06 Nov 2026. Standalone total income for the quarter was ₹412.71 crore and standalone net profit ₹45.65 crore.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹821.17 crore, up 11.1% YoY and 23.0% QoQ
- Net profit: ₹64.97 crore, up 13.7% YoY and 26.9% QoQ
- EPS: ₹6.81 basic, against ₹3.93 a year earlier
- Finance costs: ₹56.18 crore, up 56.2% YoY
Standalone
The company on its own, without its subsidiaries
- Total income: ₹412.71 crore, down 30.7% YoY and up 23.2% QoQ
- Net profit: ₹45.65 crore, up 10.3% YoY and 42.6% QoQ
- EPS: ₹4.01 basic, against ₹3.67 a year earlier
- Other income: ₹15.53 crore, up 101.7% YoY
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 821.17 | 739.19 | +11.1% | 667.55 | +23.0% | |
| Revenue from operations | 805.94 | 731.40 | +10.2% | 654.98 | +23.0% |
| Other income | 15.24 | 7.79 | +95.6% | 12.57 | +21.3% |
| 64.97 | 57.15 | +13.7% | 51.22 | +26.9% | |
| Profit before tax | 89.46 | 75.54 | +18.4% | 69.68 | +28.4% |
| Finance costs | 56.18 | 35.98 | +56.2% | 49.19 | +14.2% |
| Depreciation | 56.82 | 32.07 | +77.2% | 56.06 | +1.3% |
| Tax expense | 24.49 | 18.38 | +33.2% | 18.47 | +32.6% |
| Net profit margin | 7.91% | 7.73% | +0.18 pp | 7.67% | +0.24 pp |
| EPS, basic (₹) | 6.81 | 3.93 | +73.3% | 3.39 | +100.9% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Consolidated net profit grew faster than total income over the year, rising 13.7% against 11.1%.
Finance costs are 6.8% of total income. The filing does not state the reason for the rise in either line.
Tax expense rose 33.2% to ₹24.49 crore, which is 27.4% of profit before tax of ₹89.46 crore. Profit before tax rose 18.4%, so the tax charge grew faster than the profit before it.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 412.71 | 595.63 | -30.7% | 334.89 | +23.2% | |
| Revenue from operations | 397.19 | 587.93 | -32.4% | 328.81 | +20.8% |
| Other income | 15.53 | 7.70 | +101.7% | 6.08 | +155.3% |
| 45.65 | 41.40 | +10.3% | 32.01 | +42.6% | |
| Profit before tax | 60.73 | 54.59 | +11.2% | 41.70 | +45.7% |
| Finance costs | 47.97 | 34.75 | +38.0% | 42.09 | +14.0% |
| Depreciation | 32.33 | 27.64 | +16.9% | 31.71 | +2.0% |
| Tax expense | 15.08 | 13.19 | +14.3% | 9.69 | +55.6% |
| Net profit margin | 11.06% | 6.95% | +4.11 pp | 9.56% | +1.50 pp |
| EPS, basic (₹) | 4.01 | 3.67 | +9.3% | 2.81 | +42.7% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone total income fell 30.7% year on year, as revenue from operations dropped 32.4% to ₹397.19 crore. Other income rose 101.7% to ₹15.53 crore and now makes up 3.8% of total income, and it equals 25.6% of standalone profit before tax of ₹60.73 crore.
Standalone net profit still rose 10.3%, slower than profit before tax at 11.2%. Finance costs of ₹47.97 crore are 11.6% of total income, up 38.0% from ₹34.75 crore. Tax expense of ₹15.08 crore is 24.8% of profit before tax, and the filing does not give the reason for the change in the tax charge.
Inference
The filing reports the Bliss GVS Pharma stake of 50.07%, acquired under a Share Purchase Agreement dated 23 May 2026 and an open offer, with control from 28 Sep 2026. Goodwill of ₹10,223.94 million on that acquisition and ₹5,402.56 million on Jayhawk Fine Chemicals is provisional, and the auditor's review report is not modified, though it relies in part on other auditors' reports.
The filing does not state the consideration paid for the Bliss GVS Pharma stake or the final purchase price allocation, and it gives no reason for the rise in finance costs.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
